Hyderabad-based manufacturer of Pharmaceutical APIs and intermediates (formerly SMS Lifesciences), serving generic and innovator customers globally from USFDA/PMDA/WHO-GMP accredited plants.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 110 | 123 | 148 | 161 | 173 | 194 | 203 | 212 |
| Borrowings | 50 | 45 | 62 | 87 | 92 | 82 | 70 | 95 |
| Other Liabilities | 66 | 101 | 99 | 86 | 80 | 80 | 118 | 94 |
| Total Liabilities | 229 | 272 | 312 | 337 | 348 | 358 | 394 | 403 |
| AssetsFixed Assets | 94 | 101 | 99 | 140 | 138 | 150 | 226 | 190 |
| CWIP | 2 | 3 | 21 | 1 | 6 | 0 | 9 | 1 |
| Investments | 26 | 26 | 23 | 23 | 23 | 23 | 0 | 23 |
| Other Assets | 106 | 142 | 169 | 174 | 181 | 184 | 159 | 189 |
| Total Assets | 229 | 272 | 312 | 337 | 348 | 358 | 394 | 403 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 27 | 14 | 22 | -15 | 5 | 15 | 28 | 38 |
| Cash from Investing | -43 | -13 | -6 | -7 | -28 | -14 | -14 | -49 |
| Cash from Financing | 18 | -2 | -8 | 15 | 23 | -1 | -14 | 11 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 5 | 1 | 14 | -30 | -24 | 1 | 14 | -11 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (19.9×) and current (26.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 24.9% growth and a 20× exit, ₹1538 only delivers your return if you pay ₹1,645. The price is currently baking in 23% growth.
EPS grows 24.9%/yr for 5 years, then fades to 6% over 2, exits at 20×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 24.9% | 73.45 |
| FY28 | 24.9% | 91.74 |
| FY29 | 24.9% | 114.59 |
| FY30 | 24.9% | 143.12 |
| FY31 | 24.9% | 178.76 |
| FY32 | 15.4% ·fade | 206.38 |
| FY33 | 6.0% ·fade | 218.76 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.